TRIAL | ARM | Baseline LEVF(%) | CHF(%) | Cardiac death | Cardiac follow-up |
---|---|---|---|---|---|
HERA | NIL | >= 55 | 0 | 1 | MUGA scan or echocardiogram at 3–4 wks prior to randomization, and 3, 6, 12, 18, 24, 30, 36, and 60 mos from randomization |
H 1 YEAR | 0.6 | 0 | |||
NSABP-31 | AC followed P | >= 50 | 0.8 | 1 | MUGA scan or echocardiogram 3 wks after last AC dose, 6, 9, and 18 mos from randomization, and 3 mos after last trastuzumab dose |
AC followed PH | 4.1 | 0 | |||
NCCTGN9831 | AC followed P | >= 50 | 0.3 | 1 | MUGA scan 3 wks after last AC dose, 6 and 9 mos from randomization, and 3 mos after the last trastuzumab dose |
AC followed P and H | 2.5 | 1 | |||
AC followed PH | 3.5 | 0 | |||
BCIRG006 | AC followed D | >= 50 | 0.3 | 0 | After last AC dose, after second docetaxel dose, after end of chemotherapy, and at 3, 12 and 36 mos from randomization. At baseline, at 6 wks, 4.5 mos,13.5 mos, and 37.5 mos from randomization |
AC followed DH | 1.6 | 0 | |||
DCarbo followed H | 0.4 | 0 | |||
FIN HER | NO H | >= 50 | 3 | 0 | MUGA scan or echocardiogram before chemotherapy, after CEF, and 12 and 36 mos after completion of chemotherapy |
H | 0 | 0 |